Key facts
- It has raised $9.5M across 3 recorded rounds; the latest was Seed Round ($1.0M) in Dec 2025.
- Notable investors include Schwartz Capital Group.
- SLAM BioTherapeutics has filed 2 Form Ds with the SEC since 2023, most recently Mar 2025 ($500K sold to 1 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SLAM BioTherapeutics
Funding rounds
3 roundsAbout SLAM BioTherapeutics
Developer of antibody-drug conjugates designed to treat life-threatening blood cancers with high unmet medical need. The company offers a first-in-class ADC program and a bispecific antibody development platform, enabling oncology clinicians and patients with hematologic malignancies to access targeted therapies aimed at improving treatment outcomes.
- Sector
- Healthcare
- HQ
- Westlake Village, CA, United States
- Founded
- 2022
- Employees
- 2
- Website
- slambio.com/
- Ownership
- Privately Held (backing)
SLAM BioTherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SLAM BioTherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SLAM BioTherapeutics in its N-PORT filings yet. We sweep new filings monthly.